:: دوره 5، شماره 3 - ( 4-1392 ) ::
جلد 5 شماره 3 صفحات 115-120 برگشت به فهرست نسخه ها
Treatment of a Child with Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody: A Case Report and Review of Drug Development
چکیده:   (13423 مشاهده)
Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy with biological agents, such as the immunotoxin gemtuzumab ozogamicin has been used to induce remission in relapsed patients. Report of the case: Here, we report the first Iranian child, an 8-year-old boy, with refractory acute myeloid who was treated with gemtuzumab ozogamicin. Unfortunately, remission was not achieved and the patient died of neutropenia and septic shock. Conclusion: Gemtuzumab ozogamicin therapy in our case was not successful in achieving remission. It could be due to longstanding chemotherapy and its detrimental effects on bone marrow of the patient. Further controlled studies are necessary to learn more about efficacy and safety of this new treatment. Keywords: Childhood acute myeloid leukemia, refractory, treatment, gemtuzumab ozogamicin
متن کامل [PDF 527 kb]   (1714 دریافت)    
: پژوهشي | موضوع مقاله: Pediatric Hematology & Oncology
دریافت: ۱۳۹۱/۷/۱۹ | پذیرش: ۱۳۹۱/۱۰/۲۷ | انتشار: ۱۳۹۲/۵/۸


XML   English Abstract   Print



دوره 5، شماره 3 - ( 4-1392 ) برگشت به فهرست نسخه ها